Bioventus Stands Out Among Medical Device Peers

Got story updates? Submit your updates here. ›

Bioventus (NASDAQ:BVS) is a medical device company that focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process. The company's portfolio includes pain treatments, surgical solutions, and restorative therapies. A comparison of Bioventus to its industry peers reveals that Bioventus has higher revenue, institutional ownership, and insider ownership, though lower earnings and a higher price-to-earnings ratio.

Why it matters

This analysis highlights Bioventus' positioning within the highly competitive medical device industry. The company's strong institutional and insider ownership suggests investor confidence in its long-term growth potential, despite some financial metrics lagging behind its peers.

The details

Bioventus has a beta of 0.78, indicating its stock price is 22% less volatile than the S&P 500, while its peers have a beta of 1.78, suggesting their average stock price is 78% more volatile. Bioventus has higher revenue but lower earnings than its peers, and it is trading at a higher price-to-earnings ratio, meaning it is currently more expensive than other companies in its industry. However, Bioventus boasts stronger institutional ownership at 62.9% compared to 19.3% for its peers, as well as higher insider ownership at 33% versus 19.5% for the industry.

• Bioventus was founded in 2011 and is headquartered in Durham, North Carolina.